Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Stanford researchers have designed and prototyped an inexpensive, compact and easy-to-use smartphone lens mount for the capture of high quality photographs and videos of the eye's front and back structures.
A team of Stanford researchers has invented a product that can be used to provide relief to patients with hyperhidrosis (excessive sweating), with a particular focus on palmar hyperhidrosis (excessive sweating of the hands).
Stanford researchers have designed hydrogels that can be delivered to surgical sites in a patient's body for controlled and sustained release of bacteriophages to treat or prevent bacterial infections.
The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.
Researchers in the Mackall lab at Stanford have developed an adoptive cell therapy modification that enhances anti-tumor activity by disrupting a specific group of genes.
Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.
Stanford researchers have developed a platform for identifying highly specific modulators of cancer-associated mutant Histone Acetyltransferase 1 (HAT1) holoenzyme complexes.
To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.